康诺亚生物近日在香港联交所上市，募集资金约4亿美元。锦天城律师事务所、植德律师事务所、美迈斯律师事务所、蔡余李律师事务所与科律香港律师事务所联盟、科律律师事务所担任发行人律师；通商律师事务所、凯易律师事务所则为联席保荐人提供法律意见。

康诺亚生物成立于2016年，总部位于四川成都，主要专注于自主发现及开发自体免疫及肿瘤治疗领域创新的生物疗法。

锦天城团队由高级合伙人杜晓东、合伙人欧彬牵头领导；美迈斯团队由合伙人耿科、朱柯牵头领导；科律团队牵头合伙人为刘毅铭、余仙、蔡华；凯易团队牵头合伙人为吕梦宇。

Campbells担任发行人的离岸律师。该IPO项目的联席保荐人为摩根士丹利、中金公司、华泰国际。

O'Melveny, Cooley, K&E lead on Chinese medicine maker’s $400mln HK IPO

O'Melveny & Myers, Cooley, AllBright Law Offices, and Merits & Tree have advised Chinese medicine maker KeyMed Biosciences on its $400 million IPO in Hong Kong, with Kirkland & Ellis and Commerce & Finance Law Offices advising the joint sponsors.

Established in 2016, the Chengdu-headquartered KeyMed focuses on the in-house discovery and development of innovative biological therapies.

The O'Melveny team was led by partners Ke Geng and Ke Zhu, while the Cooley team was led by partners Liu Yiming, Michael Yu and Will Cai. 

The Kirkland team was led by partner Lu Mengyu, while the AllBright team was led by senior partner Du Xiaodong and partner Ou Bin.

Campbells was the issuer’s offshore lawyer. The joint sponsors were Morgan Stanley, CICC and Huatai International. 

To contact the editorial team, please email ALBEditor@thomsonreuters.com.